Skip Navigation
Menu
ACP Journal Club |17 September 2019

In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes

Lorraine L. Lipscombe, MD, MSc

Article, Author, and Disclosure Information
FULL TEXT
Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-30. 31189511

GIM/FP/GP:

Cardiology:

Endocrinology:

In patients ≥ 50 years of age with type 2 diabetes and previous cardiovascular (CV) disease or risk factors, does dulaglutide reduce risk for CV events?
Randomized placebo-controlled trial (Researching Cardiovascular Events with a Weekly Incretin in Diabetes [REWIND] trial). ClinicalTrials.gov NCT01394952.
Concealed.*
Blinded* (patients, {clinicians, data collectors, and outcome adjudicators}†).
Median 5.4 years.
371 clinical centers in 24 countries.
9901 adults ≥ 50 years of age (mean age 66...
FULL TEXT
PDF
Not Available
Citations
Citation

Lipscombe LL. In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes. Ann Intern Med. 2019;171:JC27. doi: 10.7326/ACPJ201909170-027

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2019;171(6):JC27.

DOI: 10.7326/ACPJ201909170-027

©
2019 American College of Physicians
0 Citations

Related Articles
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y
Annals of Internal Medicine; 165 (8): JC39
In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years
Annals of Internal Medicine; 164 (2): JC2
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization
Annals of Internal Medicine; 168 (10): JC52
In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years
Annals of Internal Medicine; 169 (12): JC67
View MoreView Less

Journal Club
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y
Annals of Internal Medicine; 165 (8): JC39
In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years
Annals of Internal Medicine; 164 (2): JC2
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization
Annals of Internal Medicine; 168 (10): JC52
In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years
Annals of Internal Medicine; 169 (12): JC67
View MoreView Less

Related Point of Care
Type 2 Diabetes
Annals of Internal Medicine; 162 (5): ITC1
Type 2 Diabetes
Annals of Internal Medicine; 152 (5): ITC3-1
Type 2 Diabetes
Annals of Internal Medicine; 146 (1): ITC1-1
Stable Ischemic Heart Disease
Annals of Internal Medicine; 171 (3): ITC17-ITC32
View MoreView Less

Related Topics
Cardiology
Coronary Risk Factors
Diabetes
Endocrine and Metabolism

Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.

PubMed Articles
Peripheral Immune Biomarkers and Neurodegenerative Diseases: A Prospective Cohort Study with 20 Years of Follow-up.
Ann Neurol 2019.
Cost Analysis of Transfusion Therapy in Coronary Artery Surgery.
Thorac Cardiovasc Surg 2019.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×